+49 30 838 62450
Atopic dermatitis and psoriasis are common inflammatory skin diseases, which cannot be treated effectively due to poor epidermal penetration (of drugs such as tacrolimus) and adverse side-effects after long-term treatment (with drugs such as dexamethasone). Core-multishell-nanocarriers (CMS-NCs) are innovative, biocompatible drug transporters, designed to enhance dermal drug uptake, concentrate drugs at the site of action and thereby minimize side-effects. The aim of this study was to investigate the impact of drug unloaded CMS-NCs on inflammatory skin diseases.
Materials and Methods:
Atopic dermatitis and psoriasis-like dermatitis were induced chemically in SKH1 or BALB/c mice, respectively. CMS-NCs or solvent were applied topically to inflamed skin or the skin of healthy controls twice daily for 5 consecutive days. The clinical course of the disease was assessed by monitoring the transepidermal water loss, erythema and water-holding capacity of the stratum corneum. Epidermal thickness and degree of inflammation were characterized histopathologically.
In both experimentally induced inflammatory skin diseases, no effects of CMS-NC were observed in any of the clinical and histological parameters studied.
Unlike other nanoparticles, unloaded CMS-NCs do not modulate atopic dermatitis and psoriasis-like dermatitis in mice. This underlines their biocompatibility and suggests that CMS-NCs may be used for drug transportation in inflammatory skin diseases.